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Effects of alendronate and risedronate therapy on hepatic
antioxidant enzyme activity and lipid peroxidation in
ovariectomized rats
Serap YALIN1, Ülkü ÇÖMELEKOĞLU2, Selda BAĞIŞ3, Mehmet BERKÖZ1, Pelin EROĞLU1

Aim: To evaluate the effects of alendronate (ALN) and risedronate (RIS), which are agents for preventing and treating
postmenopausal osteoporosis, on hepatic antioxidant enzyme activity and lipid peroxidation in ovariectomized rats.
Materials and methods: Thirty-two female rats were randomly assigned to 4 separate groups. All of the groups, except
the control group, were ovariectomized. Included in the 4 groups were a control group (C), an ovariectomized group
(OVX), an ovariectomized group treated with alendronate (OVX-ALN), and an ovariectomized group treated with
risedronate (OVX-RIS). Ten weeks after an ovariectomy, the OVX-ALN rats were administered 1.75 mg/kg of their body
weight with alendronate sodium; and the OVX-RIS rats were administered 0.5 mg/kg of their body weight with
risedronate sodium. Both doses were administered by gavage twice per week for 12 weeks. At the end of the treatment
period, the liver enzyme activity levels of superoxide dismutase (SOD) and catalase (CAT) and malondialdehyde (MDA)
levels were measured.
Results: There were significantly elevated levels of MDA observed in the OVX and OVX-ALN groups, whereas the MDA
concentration significantly decreased in the OVX-RIS group when compared to the control animals. The SOD activity
was significantly higher in the OVX and OVX-ALN groups, but there was no statistically significant difference in the SOD
activity in the OVX-RIS group when compared with that of the control group. Moreover, CAT activity declined
significantly in the OVX group and was elevated in the OVX-ALN group, according to the control group. No significant
change in CAT activity was observed in the OVX-RIS group.
Conclusion: Alendronate increases the effect of ovariectomy on lipid peroxidation, and induces oxidative stress; however,
risedronate prevents oxidative stress caused by an ovariectomy.
Key words: Alendronate, risedronate, ovariectomy, antioxidants

Overektomili sıçanlarda alendronat ve risedronat uygulamasının hepatik
antioksidan enzim aktivitesi ve lipid peroksidasyonu üzerine etkileri
Amaç: Postmenopozal osteoporozu engellemek ve tedavi etmek amacıyla kullanılan alendronat (ALN) ve risedronat
(RIS)’ın overektomili sıçanlarda hepatik antioksidan enzim aktivitesi ve lipid peroksidasyonu üzerine olan etkisini
değerlendirmek.
Yöntem ve gereç: Otuz iki dişi sıçan kontrol grubu (C), overektomili grup (OVX), alendronat uygulanan overektomili
grup (OVX-ALN) ve risedronat uygulanan overektomili grup (OVX-RIS) şeklinde randomize olarak ayrıldı. Kontrol
grubu hariç tüm gruplara overektomi uygulandı. Overektomiden 10 hafta sonra, OVX-ALN grubuna 1,75 mg/kg
alendronat sodyum and OVX-RIS grubuna ise 0,5 mg/kg risedronat sodyum gavaj yoluyla 12 hafta verildi. Uygulama
sonunda karaciğer superoksit dismutaz (SOD), katalaz (CAT) enzim aktiviteleri ve malondialdehit (MDA) düzeyleri
ölçüldü.
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Bulgular: OVX ve OVX-ALN gruplarında MDA düzeyleri kontrol grubu ile karşılaştırıldığında anlamlı derecede
yükselmiş iken OVX-RIS grubunda MDA düzeyi anlamlı derecede düşmüş olarak gözlendi. SOD aktivitesi ise kontrol
grubuyla karşılaştırıldığında OVX ve OVX-ALN gruplarında anlamlı derecede yükselmiş iken OVX-RIS grubunda
anlamlı bir farklılık gözlenmedi. CAT aktivitesi kontrol grubuna göre OVX grubunda anlamlı derecede düşmüş iken
OVX-ALN grubunda yüksek gözlendi. CAT aktivitesi OVX-RIS grubunda anlamlı bir farklılık göstermedi.
Sonuç: Alendronat overektominin lipid peroksidasyonu üzerine etkisini arttırır iken, risedronat overektominin neden
olduğu oksidatif stresi engellemektedir.
Anahtar sözcükler: Alendronat, risedronat, overektomi, antoksidan

Introduction
Bisphosphonates are commonly prescribed to
stabilize bone loss caused by osteoporosis in millions
of postmenopausal women. The strategy in the
treatment of osteoporosis is to inhibit the resorption
of trabecular bone by osteoclasts, and hence preserve
its density. For this purpose, oral bisphosphonates
need to be prescribed and include etidronate,
risedronate, tiludronate, and alendronate (1,2).
The bisphosphonates share the pyrophosphate
structure, which characterizes the pharmacological
group. They are structural analogs of pyrophosphates
with specific activity upon bone. Bisphosphonates
were formerly classified according to the chemical
group added to the base pyrophosphoric nucleus on
its R2 side chain (3-6). The second generation
includes the aminobisphosphonates with a terminal
amino group (e.g. alendronate and pamidronate),
while the third generation is characterized by having
a cyclic side chain, as in the case of risedronate (3).
Alendronate and risedronate are considered firstline therapy for the prevention and treatment of
osteoporosis in postmenopausal women, as well as for
the treatment of osteoporosis in men. Alendronate (4amino-1-hydroxybutylidine-1,1-bisphosphonate)
increases bone mineral density (BMD), and decreases
fracture incidents over 4 years in postmenopausal
women with osteoporosis (7-9). These beneficial
clinical effects are associated with a marked
antiresorptive effect, characterized by decreased bone
remodeling by up to 90%. Alendronate and
risedronate are also approved for the treatment of
glucocorticoid induced osteoporosis in men.
Risedronate is a pyridinyl bisphosphonate that exerts
its clinical effects through binding to hydroxyapatite
in bone tissue and inhibiting osteoclast activity
(10,11).
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Reactive oxygen species (ROS) may play
important roles in various biological reactions, and
they have been suggested to be effective in the
pathogenesis of many diseases. ROS may cause tissue
damage by affecting the cell membrane, genetic
material, enzymatic pathways, and connective tissue
structures. The relationship between ROS and human
diseases is dependent upon the balance between the
ROS and antioxidants. Cells are protected against
oxidative damage by various systems (enzymatic,
nonenzymatic), and molecules, such as superoxide
dismutase (SOD), catalase (CAT) and glutathione
peroxidase (GSH-Px), are well-known scavenger
enzymes that protect the cell from oxidative stress
(12-14).
It has been suggested by several researchers that
enzymatic and/or non-enzymatic antioxidant systems
are impaired in osteoporosis, and thus osteoporotic
patients are exposed to oxidative damage (15,16). The
different activities of antioxidant enzymes, namely
SOD and GSH-Px, have been reported with
osteoporosis (16-19). It has also been supposed that
osteoporotic patients are more prone to lipid
peroxidation because of a reduced antioxidant defense
system (17,19).
The objective of this study was to investigate
whether alendronate and risedronate could influence
the lipid peroxidation and antioxidative property in
the livers of ovariectomized rats. To the best of our
knowledge, the effects of alendronate and risedronate
on lipid peroxidation, and antioxidant enzyme levels
in ovariectomized rats have not yet been studied.
Materials and methods
All experimental protocols were approved by the
Mersin University School of Medicine Animal Care
and Use Committee. Sprague-Dawley female rats
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(200-250 g) were kept in a room with a constant
temperature of 22 ± 1 °C, and 12 h light and dark
cycles, they were fed a standard rat chow, and had
access to water ad libitum.
This study was performed on 4 groups of animals
with each group consisting of 8 rats: (1) control group
(C), (2) the ovariectomized group (OVX), (3) the
ovariectomized group treated with alendronate
(OVX-ALN), and (4) the ovariectomized group
treated with risedronate (OVX-RIS).
Thirty-two rats were anesthetized with ketamine
(Ketalar, Eczacıbaşı Pharmaceutical Co.) and then
underwent a bilateral ovariectomy via ventral
incision. Ten weeks after the ovariectomy, the OVXALN rats were administered 1.75 mg/kg of their body
weight alendronate sodium, and the OVX-RIS rats
were administered 0.5 mg/kg of their body weight
risedronate sodium. Both doses were administered by
gavage twice per week for 12 weeks. The BMD
measurement is widely used for detecting
osteoporosis. For this reason, we used dual-energy Xray absorptiometry (Norland XR 45, Norland
Scientific Instruments, Fort Atkinson, WI, USA) with
a scan speed of 1 mm/s, and a resolution of 0.5 ×
0.5 mm. Before taking the measurement, the
instrument was calibrated by means of a Norland
phantom. The BMD (in milligrams per square
centimeter) was determined by the analysis of the
femoral shaft.
After the treatment, the animals were killed by
decapitation under ketamine anesthesia. The livers
were quickly excised, rinsed in ice-cold 0.175 M
KCl/25 mM Tris–HCl (pH 7.4) to remove the blood,
weighed, finely minced in the same solution, and
homogenized by means of a homogenizer with a
Teflon pestle. The liver homogenates were centrifuged
at 10,000 ×g for 15 min. The supernatants were then
used for lipid peroxidation determination, and
antioxidant enzyme assays.
Tissue SOD and CAT activity determination
The SOD activity was measured by the inhibition
of nitroblue tetrazolium (NBT) reduction due to O2
generated by the xanthine/xanthine oxidase system
(20). One unit of SOD activity was defined as the
amount of protein causing 50% inhibition of the NBT
reduction rate.

The CAT activity of tissues was determined
according to the method of Aebi (21). The enzymatic
decomposition of H2O2 was followed directly by the
decrease in absorbance at 240 nm. The difference in
absorbance per unit time was used as a measure of
CAT activity. The enzyme activity is given in U/mg of
protein.
Determination of malondialdehyde levels
The levels of malondialdehyde (MDA) in
homogenized tissue, as an index of lipid peroxidation,
were determined by a thiobarbituric acid reaction
using the method of Yagi (22).
Determination of protein content
The tissue protein content was measured by a
procedure similar to that documented by Lowry et al.
(23) using bovine serum albumin as a standard.
Statistical analysis
The statistical analysis was carried out using SPSS
11.0. After obtaining normal distribution
(Kolmogorov-Smirnov), the data were expressed as a
mean ± standard deviation (SD), and the Bonferroni
significant difference test was used to compare
different groups. Values of P < 0.05 were regarded as
significant.
Results
The BMD values were 0.145 ± 0.025 in the control
group, 0.103 ± 0.044 in the OVX group, 0.141 ± 0.047
in the OVX-ALN group, and 0.146 ± 0.031 in the
OVX-RIS group. The BMD value in the OVX group
was significantly lower than that in the other groups
(P < 0.05).
The results regarding lipid peroxidation and
antioxidant activity are presented in the Table. The
liver’s MDA levels were significantly increased (P <
0.05) in the OVX and OVX-ALN groups, whereas the
MDA concentration was significantly decreased (P <
0.05) in the OVX-RIS group compared to the control
group. The SOD activity was found to be higher in the
OVX and OVX-ALN groups; however, there was no
statistically significant difference in the SOD activity
in the OVX-RIS group when compared with that of
the control group. Furthermore, CAT activity
declined significantly in the OVX group and was
elevated in the OVX-ALN group compared to the
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Table. Liver MDA concentration, and SOD and CAT activity in the control, OVX, OVX-ALN, and OVX-RIS groups.
Variables

MDA (nmol/mg protein)
SOD (U/mg protein)
CAT (U/mg protein)

Control
(n = 8)

OVX
(n = 8)

OVX-ALN
(n = 8)

1.50 ± 0.66
10.61 ± 1.62
502.31 ± 56.13

2.38 ± 0.39*
19.22 ± 2.31*
276.43 ± 80.75*

3.94 ± 1.74*
42.32 ± 2.54*,a
,a
783.38 ± 96.58*

,a

OVX-RIS
(n = 8)
0.48 ± 0.12*,a
13.72 ± 1.87
496.23 ± 36.59a

Data are means ± SD
* Significant difference from control at P < 0.05
a
Significant difference from OVX at P < 0.05

control group. No significant change in CAT activity
was observed in the OVX-RIS group (Table). When
the OVX group was compared to the OVX-ALN and
OVX-RIS groups, the MDA concentration was
significantly higher in the OVX-ALN treated animals,
while it was lower in the OVX-RIS treated animals.
The SOD activity increased in the OVX-ALN group;
however, no significant variation in the SOD activity
was obtained from the OVX-RIS group. The CAT
activity was significantly elevated in both the OVXALN and OVX-RIS groups.
Discussion
Bisphosphonates are now well established as
successful antiresorptive agents for the prevention and
treatment of osteoporosis. In particular, alendronate
and risedronate are approved as therapies for
osteoporosis in many countries (7,24), and both drugs
have a high affinity for bone mineral and function by
reducing bone turnover by inhibiting osteoclastmediated resorption (25-27). Clinical studies have
demonstrated the clinical efficacy of alendronate and
risedronate in reducing bone loss, and in the vertebral
and non-vertebral fractures resulting from
osteoporosis (28-31).
In addition to the effects of alendronate and
risedronate on the bone in postmenopausal women,
there are several studies that are related to the effects
of alendronate, risedronate, and ovariectomy on the
antioxidant system and lipid peroxidation separately
(32-34). However, there are no reports concerning the
influence of alendronate and risedronate on the
antioxidant status and lipid peroxidation in
ovariectomized rats. MDA is a major oxidation
product of peroxidized polyunsaturated fatty acids,
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and increased MDA content is an important indicator
of lipid peroxidation (35).
In the present study, we used the ovariectomized
rat model to show postmenopausal osteoporosis. The
ovariectomized rat is the most frequently used model
for osteoporosis (36,37). This model exhibits a
progressive loss of bone matrix through a process that
is similar to that which occurs during
postmenopausal osteoporosis (36,38,39).
The results of the present study show that the
liver’s MDA levels and the SOD activity were
significantly higher; however, CAT levels were
significantly lower in the OVX group than in the
control group. The increased SOD and reduced CAT
in the OVX group would lead to the accumulation of
H2O2 (40), a highly toxic metabolite for cells (41).
H2O2 may be converted to H2O, either by CAT or
GSH-Px. H2O2 is decomposed to O2 and H2O by CAT
at high concentrations, while GSH-Px serves for H2O2
degradation at lower concentrations (42).
Observation of lower CAT levels in the OVX rats
suggests that OVX may inhibit CAT activity and cause
H2O2 accumulation, thus resulting in oxidative
damage. Muthusami et al. (43) examined oxidative
stress parameters in rat bone tissue homogenates after
a bilateral ovariectomy. They demonstrated that SOD
and GSH-Px activity decreased while lipid
peroxidation as well as H2O2 concentration increased
in the bones of ovariectomized animals when
compared to the control group. Ha (44) showed that
ovariectomy increased the levels of MDA and
decreased levels of the antioxidative enzymes SOD,
CAT, and GSH-Px. In our previous study (34), we
found that OVX leads to an increase in MDA levels
and a decrease in the SOD and CAT activity in the
livers of ovariectomized rats. A decrease in the activity
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of any one of the antioxidant enzymes would likely
lead to cellular death due to an accumulation of H2O2,
which is an extremely cytotoxic chemical species. An
ovariectomy leading to estrogen insufficiency results
in general changes in metabolism that can be seen in
the liver. The lack of protective estrogen is reflected
in the alterations of an antioxidative/oxidative balance
in the liver (45).
In the OVX-ALN group enhanced MDA levels as
well as SOD and CAT activity in the osteoporotic
livers of all groups were observed. The increase in
MDA concentration, in spite of increased SOD and
CAT activity, could have been due to the
overproduction of ROS that exceeded the capacity of
these antioxidant enzymes. In the literature, there are
limited studies related to the influence of alendronate
on lipid peroxidation and antioxidants. Şener and
coworkers (32) showed that MDA concentration
increased in the alendronate group, and they reported
that alendronate induced oxidative gastric damage in
rats by increasing lipid peroxidation and decreasing
glutathione levels. Our results are in agreement with
the data of Sener et al. (32).
In the OVX-RIS group, the MDA levels decreased
and the activity of SOD and CAT remained
unchanged when compared to the control group. The
unchanged antioxidant enzyme activity may be due
to the declined MDA levels, and, as a result, the SOD

and CAT enzymes may not be induced. These
findings suggest that risedronate can prevent
oxidative damage by decreasing the MDA
concentration. Ozgocmen et al. (33) assessed the in
vivo effects of calcitonin, risedronate, and raloxifene
on the erythrocyte oxidant-antioxidant status in
women with postmenopausal osteoporosis. They
showed that MDA levels declined but the activity of
SOD and CAT were not changed by the
administration of risedronate (33).
Alendronate is used in many countries to treat
osteoporosis, and it has been extensively evaluated in
clinical trials, lasting up to 10 years (7,8). Our results
demonstrated that alendronate increases the effect of
an ovariectomy on lipid peroxidation and induces
oxidative stress in the liver of ovariectomized rats.
However, when risedronate was given to
ovariectomized rats, the lipid peroxidation decreased
when compared to the alendronate treated group, thus
suggesting a decrease in oxidative stress. As a result, it
may be suggested that risedronate possesses some
antioxidant properties, and can contribute to the
effectiveness of therapy for osteoporosis.
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